NCT03330457View on ClinicalTrials.gov

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 6, 2015

Primary Completion Date

February 22, 2016

Study Completion Date

February 22, 2016

Conditions
Bleeding
Interventions
BIOLOGICAL

Andexanet alfa (bolus)

fXa inhibitor antidote

DRUG

Betrixaban 80 mg PO QD

fXa inhibitor

BIOLOGICAL

Andexanet alfa (infusion IV)

fXa inhibitor antidote

Trial Locations (1)

90630

WCCT Global, Cypress

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT03330457 - A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing | Biotech Hunter | Biotech Hunter